SCHEMBL12371766

SCHEMBL12371766

CN1CCC(Nc2ncc3[nH]c(=O)n(Cc4ccccc4Cl)c3n2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.50
ADORA1 P30542 2/20 0.50
MAPK7 Q13164 1/20 0.47
ACHE P22303 1/20 0.45
BACE1 P56817 1/20 0.45
ALDH1A1 P00352 3/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 2/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
MAP4K1 Q92918 1/20 0.43
USP1 O94782 2/20 0.42
CDK2 P24941 2/20 0.42
MAPK8 P45983 2/20 0.42
JUN P05412 1/20 0.42
MAPK9 P45984 1/20 0.42
THRB P10828 1/20 0.42
LCK P06239 1/20 0.42
MAPK14 Q16539 1/20 0.42
ROCK2 O75116 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12371801 0.89 ADORA2A (0.50) ADORA2AADORA1MAPK7ALDH1A1MAP4K1
SCHEMBL12371706 0.85 ALDH1A1 (0.42) ADORA2AADORA1ALDH1A1TSHRHSD17B10
SCHEMBL12371758 0.79 CACNA1G (0.44) ADORA2AADORA1ALDH1A1TSHRHSD17B10
SCHEMBL12371700 0.78 CYP2C9 (0.54) ADORA2AADORA1ALDH1A1TSHRHSD17B10
SCHEMBL12371789 0.77 CACNA1G (0.49) ALDH1A1TSHRHSD17B10GAAHTT
SCHEMBL12371797 0.77 ALDH1A1 (0.43) ALDH1A1TSHRHSD17B10USP1ADORA3
SCHEMBL12371785 0.76 BCDIN3D (0.41) ADORA2AADORA1ALDH1A1TSHRHSD17B10
SCHEMBL12371635 0.76 PRKCQ (0.48) ADORA2AADORA1ALDH1A1TSHRHSD17B10
SCHEMBL12371647 0.76 PRKCQ (0.48) ADORA2AADORA1ALDH1A1TSHRHSD17B10
SCHEMBL12371664 0.76 PRKCQ (0.48) ADORA2AADORA1ALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989459-B2 Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one PHARMACOPEIA, LLC (US) 2011-08-02 US disclosed
US-7989459-B2 Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one PHARMACOPEIA, LLC (US) 2011-08-02 US disclosed
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-04-10 US disclosed
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PRKCE, PRKCH, PRKCQ ADORA2A 995/4885ADORA1 1307/4885MAPK7 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.